Loading...
•
Sep 30, 2022
Syndax Q3 2022 Earnings Report
Syndax reported third quarter financial results and provided a business update.
Key Takeaways
Syndax Pharmaceuticals reported its Q3 2022 financial results, highlighting positive data from the AUGMENT-101 trial of revumenib and the completion of enrollment in the pivotal AGAVE-201 trial of axatilimab. The company is on track for two U.S. registrational filings by the end of 2023.
Updated data from the Phase 1 portion of the AUGMENT-101 trial demonstrated a CR/CRh rate of 30% and a median durability of response of 9.1 months.
Enrollment is complete in the pivotal Phase 2 AGAVE-201 trial of axatilimab in patients with cGVHD.
The company remains on track for two U.S. registrational filings by the end of 2023.
Updated positive data from the Phase 1 portion of the ongoing AUGMENT-101 trial of revumenib will be featured during two oral presentations at the American Society of Hematology (ASH) Annual Meeting in December.
Forward Guidance
For the full year of 2022, the Company is lowering its expectations of both research and development and total operating expenses. The updated guidance reflects the benefits derived from the shared expenses for our axatilimab cGVHD development program.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...